{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:47:13Z","timestamp":1790758033533,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A2C1004582"],"award-info":[{"award-number":["NRF-2019R1A2C1004582"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12272-023-01472-z","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T12:02:53Z","timestamp":1702036973000},"page":"939-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes"],"prefix":"10.1007","volume":"46","author":[{"given":"Chang-Keun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pureum","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon-Gon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-1981","authenticated-orcid":false,"given":"Seok-Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ik","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"9","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/dmd.114.058099","volume":"42","author":"K Abduljalil","year":"2015","unstructured":"Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan (2015) Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos 42(9):1478\u20131484. https:\/\/doi.org\/10.1124\/dmd.114.058099","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.bcp.2008.07.006","volume":"76","author":"A Alonen","year":"2008","unstructured":"Alonen A, Finel M, Kostiainen R (2008) The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76(6):763\u2013772. https:\/\/doi.org\/10.1016\/j.bcp.2008.07.006","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/bmc.1154","volume":"23","author":"SK Bae","year":"2009","unstructured":"Bae SK, Kim MJ, Shim EJ, Cho DY, Shon JH, Liu KH, Kim EY, Shin JG (2009) HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. Biomed Chromatogr 23(6):568\u2013572. https:\/\/doi.org\/10.1002\/bmc.1154","journal-title":"Biomed Chromatogr"},{"issue":"4","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2125.2010.03853.x","volume":"71","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Jang CG, Lee SY (2011a) Effects of CYP2C9*1\/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 71(4):550\u2013555. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03853.x","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/aps.2011.100","volume":"32","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Kim MJ, Oh DH, Keum SK, Park JI, Kim BH, Bang HK, Oh SG, Kang BS, Park HJ, Kim HD, Ha JH, Shin HJ, Kim YH, Na HS, Chung MW, Jang CG, Lee SY (2011b) Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32(10):1303\u20131308. https:\/\/doi.org\/10.1038\/aps.2011.100","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"1472_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5414\/cp201467","volume":"50","author":"JW Bae","year":"2012","unstructured":"Bae JW, Choi CI, Lee HI, Lee YJ, Jang CG, Lee SY (2012) Effects of CYP2C9*1\/*3 and *1\/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. Int J Clin Pharmacol Ther 50(9):683\u2013689. https:\/\/doi.org\/10.5414\/cp201467","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12272-020-01293-4","volume":"43","author":"JW Bae","year":"2020","unstructured":"Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207\u20131213. https:\/\/doi.org\/10.1007\/s12272-020-01293-4","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1472_CR8","first-page":"288","volume":"27","author":"M Bourri\u00e9","year":"1999","unstructured":"Bourri\u00e9 M, Meunier V, Berger Y, Fabre G (1999) Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 27(2):288\u2013296","journal-title":"Drug Metab Dispos"},{"issue":"S9","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"311S","DOI":"10.1016\/S0895-7061(97)00391-9","volume":"10","author":"HR Brunner","year":"1997","unstructured":"Brunner HR (1997) The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 10(S9):311S-317S. https:\/\/doi.org\/10.1016\/S0895-7061(97)00391-9","journal-title":"Am J Hypertens"},{"issue":"2","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12272-018-1099-y","volume":"42","author":"JY Byeon","year":"2019","unstructured":"Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY (2019) Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 42(2):182\u2013190. https:\/\/doi.org\/10.1007\/s12272-018-1099-y","journal-title":"Arch Pharm Res"},{"issue":"8","key":"1472_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12272-023-01462-1","volume":"46","author":"JY Byeon","year":"2023","unstructured":"Byeon JY, Cho CK, Kang P, Kim SH, Jang CG, Lee SY, Lee YJ (2023) Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone. Arch Pharm Res 46(8):713\u2013721. https:\/\/doi.org\/10.1007\/s12272-023-01462-1","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1472_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/s0731-7085(01)00413-7","volume":"26","author":"E Cagigal","year":"2001","unstructured":"Cagigal E, Gonzalez L, Alonso RM, Jim\u00e9nez RM (2001) pKa determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. J Pharm Biomed Anal 26(3):477\u2013486. https:\/\/doi.org\/10.1016\/s0731-7085(01)00413-7","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"1472_CR13","first-page":"408","volume":"26","author":"TJ Chando","year":"1998","unstructured":"Chando TJ, Everett DW, Kahle AD, Starrett AM, Vachharajani N, Shyu WC, Kripalani KJ, Barbhaiya RH (1998) Biotransformation of irbesartan in man. Drug Metab Dispos 26(5):408\u2013417","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1472_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1046\/j.1523-1755.2002.00200.x","volume":"61","author":"AB Chapman","year":"2002","unstructured":"Chapman AB, Schwartz GL, Boerwinkle E, Turner ST (2002) Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 61(3):1047\u20131055. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00200.x","journal-title":"Kidney Int"},{"issue":"8","key":"1472_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/bdd.1961","volume":"36","author":"H Chapy","year":"2015","unstructured":"Chapy H, Klieber S, Brun P, Gerbal-Chaloin S, Boulenc X, Nicolas O (2015) PBPK modeling of irbesartan: incorporation of hepatic uptake. Biopharm Drug Dispos 36(8):491\u2013506. https:\/\/doi.org\/10.1002\/bdd.1961","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1358\/mf.2006.28.1.962773","volume":"28","author":"G Chen","year":"2006","unstructured":"Chen G, Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z, Liu X, Zhang Y, Xing H, Wang B, Yu Y, Xu X (2006) CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients. Methods Find Exp Clin Pharmacol 28(1):19\u201324. https:\/\/doi.org\/10.1358\/mf.2006.28.1.962773","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"11","key":"1472_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12272-021-01357-z","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 44(11):1037\u20131049. https:\/\/doi.org\/10.1007\/s12272-021-01357-z","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1472_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s12272-021-01361-3","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res 44(12):1076\u20131090. https:\/\/doi.org\/10.1007\/s12272-021-01361-3","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1472_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12272-022-01388-0","volume":"45","author":"CK Cho","year":"2022","unstructured":"Cho CK, Kang P, Park HJ, Ko E, Mu CY, Lee YJ, Choi CI, Kim HS, Jang CG, Bae JW, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Arch Pharm Res 45(5):352\u2013366. https:\/\/doi.org\/10.1007\/s12272-022-01388-0","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1472_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12272-022-01422-1","volume":"46","author":"CK Cho","year":"2023","unstructured":"Cho CK, Byeon JY, Kang P, Park JI, Jang CG, Lee SY, Choi CI, Bae JW, Lee YJ (2023a) Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone. Arch Pharm Res 46(1):59\u201364. https:\/\/doi.org\/10.1007\/s12272-022-01422-1","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1472_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12272-022-01423-0","volume":"46","author":"CK Cho","year":"2023","unstructured":"Cho CK, Byeon JY, Kang P, Park HJ, Ko E, Mu CY, Jang CG, Lee SY, Lee YJ (2023b) Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects. Arch Pharm Res 46(2):111\u2013116. https:\/\/doi.org\/10.1007\/s12272-022-01423-0","journal-title":"Arch Pharm Res"},{"issue":"6","key":"1472_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1742-7843.2011.00751.x","volume":"109","author":"CI Choi","year":"2011","unstructured":"Choi CI, Kim MJ, Jang CG, Park YS, Bae JW, Lee SY (2011) Effects of the CYP2C9*1\/*13 genotype on the pharmacokinetics of lornoxicam. Basic Clin Pharmacol Toxicol 109(6):476\u2013480. https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00751.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1472_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00228-011-1098-0","volume":"68","author":"CI Choi","year":"2012","unstructured":"Choi CI, Kim MJ, Chung EK, Lee HI, Jang CG, Bae JW, Lee SY (2012) CYP2C9 *3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol 68(2):149\u2013154. https:\/\/doi.org\/10.1007\/s00228-011-1098-0","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1185\/03007995.2014.980886","volume":"31","author":"HY Choi","year":"2015","unstructured":"Choi HY, Lim HS, Kim YH, Jeon HS, Kim MJ, Lee SH, Jung JH, Lee YK, Kim HJ, Bae KS (2015) Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin 31(2):229\u2013241. https:\/\/doi.org\/10.1185\/03007995.2014.980886","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrneph.2015.176","volume":"12","author":"RM Cooper-DeHoff","year":"2016","unstructured":"Cooper-DeHoff RM, Johnson JA (2016) Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol 12(2):110\u2013122. https:\/\/doi.org\/10.1038\/nrneph.2015.176","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1472_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm8010001","volume":"8","author":"AK Daly","year":"2017","unstructured":"Daly AK, Rettie AE, Fowler DM, Miners JO (2017) Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med 8(1):1. https:\/\/doi.org\/10.3390\/jpm8010001","journal-title":"J Pers Med"},{"issue":"1","key":"1472_CR27","first-page":"79","volume":"28","author":"H Davi","year":"2000","unstructured":"Davi H, Tronquet C, Miscoria G, Perrier L, DuPont P, Caix J, Simiand J, Berger Y (2000) Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metab Dispos 28(1):79\u201388","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1472_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1590\/S0103-50532011000200008","volume":"22","author":"HS El-Desoky","year":"2011","unstructured":"El-Desoky HS, Ghoneim MM, Habazy A (2011) Voltammetry of irbesartan drug in pharmaceutical formulations and human blood: quantification and pharmacokinetic studies. J Braz Chem Soc 22(2):239\u2013247. https:\/\/doi.org\/10.1590\/S0103-50532011000200008","journal-title":"J Braz Chem Soc"},{"key":"1472_CR29","unstructured":"European Medicines Agency (2023) Aprovel: EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aprovel-epar-product-information_en.pdf. Accessed 06 Nov 2023"},{"issue":"6","key":"1472_CR30","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2165\/00003495-199754060-00007","volume":"54","author":"JC Gillis","year":"1997","unstructured":"Gillis JC, Markham A (1997) Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 54(6):885\u2013902. https:\/\/doi.org\/10.2165\/00003495-199754060-00007","journal-title":"Drugs"},{"issue":"6","key":"1472_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1124\/dmd.105.003616","volume":"33","author":"Y Guo","year":"2005","unstructured":"Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H (2005) Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33(6):749\u2013753. https:\/\/doi.org\/10.1124\/dmd.105.003616","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1472_CR32","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1097\/00004872-200210000-00030","volume":"20","author":"P Hallberg","year":"2002","unstructured":"Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, \u00d6hman KP, Nystr\u00f6m F, Melhus H (2002) The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 20(10):2089\u20132093. https:\/\/doi.org\/10.1097\/00004872-200210000-00030","journal-title":"J Hypertens"},{"issue":"3","key":"1472_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjhyper.2006.09.006","volume":"20","author":"TP Hiltunen","year":"2007","unstructured":"Hiltunen TP, Suonsyrj\u00e4 T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, Tikkanen I, Tilvis R, Pentik\u00e4inen PJ, Virolainen J, Kontula K (2007) Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 20(3):311\u2013318. https:\/\/doi.org\/10.1016\/j.amjhyper.2006.09.006","journal-title":"Am J Hypertens"},{"key":"1472_CR34","unstructured":"Hindmarsh AC, Reynolds DR, Serban R, Woodward CS, Gardner, DJ, Cohen SD, Taylor A, Peles S, Banks L, Shumaker D (2023) Open Systems Pharmacology Suite Manual version 11 update 1. https:\/\/docs.open-systems-pharmacology.org\/copyright. Accessed 06 Nov 2023"},{"issue":"4","key":"1472_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/cpt.1928","volume":"108","author":"P Hirvensalo","year":"2020","unstructured":"Hirvensalo P, Tornio A, Launiainen T, Paile-Hyv\u00e4rinen M, Tapaninen T, Neuvonen M, Backman JT, Niemi M (2020) UGT1A3 and sex are major determinants of telmisartan pharmacokinetics\u2014a comprehensive pharmacogenomic study. Clin Pharmacol Ther 108(4):885\u2013895. https:\/\/doi.org\/10.1002\/cpt.1928","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1472_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-005-0976-8","volume":"61","author":"X Hong","year":"2005","unstructured":"Hong X, Zhang S, Mao G, Jiang S, Zhang Y, Yu Y, Tang G, Xing H, Xu X (2005) CYP2C9* 3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Phamracol 61(9):627\u2013634. https:\/\/doi.org\/10.1007\/s00228-005-0976-8","journal-title":"Eur J Clin Phamracol"},{"issue":"4","key":"1472_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF03190465","volume":"31","author":"XH Huang","year":"2006","unstructured":"Huang XH, Li J, Qiu FR, Xie HT, Huang JH, Li JC, Zheng QS (2006) PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. Eur J Drug Metab Pharmacokinet 31(4):259\u2013264. https:\/\/doi.org\/10.1007\/BF03190465","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"1472_CR38","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1021\/acs.molpharmaceut.8b00138","volume":"15","author":"S Izumi","year":"2018","unstructured":"Izumi S, Nozaki Y, Kusuhara H, Hotta K, Mochizuki T, Komori T, Maeda K, Sugiyama Y (2018) Relative activity factor (RAF)-based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes. Mol Pharm 15(6):2277\u20132288. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00138","journal-title":"Mol Pharm"},{"key":"1472_CR39","doi-asserted-by":"publisher","first-page":"126777","DOI":"10.1016\/j.ijbiomac.2023.126777","volume":"249","author":"SH Jeong","year":"2023","unstructured":"Jeong SH, Jang JH, Lee YB (2023) P-glycoprotein mechanical functional analysis using in silico molecular modeling: Pharmacokinetic variability according to ABCB1 c.2677G > T\/A genetic polymorphisms. Int J Biol Macromol 249:126777. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.126777","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"1472_CR40","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12272-020-01300-8","volume":"43","author":"EH Jung","year":"2020","unstructured":"Jung EH, Lee YJ, Kim DH, Kang P, Lim CW, Cho CK, Jang CG, Lee SY, Bae JW (2020) Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Arch Pharm Res 43(12):1356\u20131363. https:\/\/doi.org\/10.1007\/s12272-020-01300-8","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1472_CR41","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s12272-021-01363-1","volume":"44","author":"EH Jung","year":"2021","unstructured":"Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res 44(12):1109\u20131119. https:\/\/doi.org\/10.1007\/s12272-021-01363-1","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1472_CR42","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12272-023-01448-z","volume":"46","author":"P Kang","year":"2023","unstructured":"Kang P, Cho CK, Jang CG, Lee SY, Lee YJ, Choi CI, Bae JW (2023) Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects. Arch Pharm Res 46(5):438\u2013447. https:\/\/doi.org\/10.1007\/s12272-023-01448-z","journal-title":"Arch Pharm Res"},{"key":"1472_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105498","volume":"153","author":"E Karatza","year":"2020","unstructured":"Karatza E, Karalis V (2020) Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. Eur J Pharm Sci 153:105498. https:\/\/doi.org\/10.1016\/j.ejps.2020.105498","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1472_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-020-01643-x","volume":"21","author":"N Kaur","year":"2020","unstructured":"Kaur N, Thakur PS, Shete G, Gangwal R, Sangamwar AT, Bansal AK (2020) Understanding the oral absorption of irbesartan using biorelevant dissolution testing and PBPK modeling. AAPS PharmSciTech 21(3):1\u201313. https:\/\/doi.org\/10.1208\/s12249-020-01643-x","journal-title":"AAPS PharmSciTech"},{"key":"1472_CR45","unstructured":"Khullar P, Kolhe V, Kulkarni A, Patel S, Phadke Y, Saravanan D, Shingte M (2015) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application. United States Patent No. US009173848B2. https:\/\/patentimages.storage.googleapis.com\/90\/e0\/b6\/0df075f6d20b3a\/US9173848.pdf. Accessed 06 Nov 2023"},{"issue":"3","key":"1472_CR46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s12272-016-0861-2","volume":"40","author":"SH Kim","year":"2017","unstructured":"Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW, Lee YJ, Jang CG, Lee SY (2017) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch Pharm Res 40(3):382\u2013390. https:\/\/doi.org\/10.1007\/s12272-016-0861-2","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1472_CR47","doi-asserted-by":"publisher","first-page":"12405","DOI":"10.1038\/s41598-018-30841-8","volume":"8","author":"SH Kim","year":"2018","unstructured":"Kim SH, Byeon JY, Kim YH, Lee CM, Lee YJ, Jang CG, Lee SY (2018) Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Sci Rep 8(1):12405. https:\/\/doi.org\/10.1038\/s41598-018-30841-8","journal-title":"Sci Rep"},{"issue":"7","key":"1472_CR48","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12272-021-01346-2","volume":"44","author":"YH Kim","year":"2021","unstructured":"Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713\u2013724. https:\/\/doi.org\/10.1007\/s12272-021-01346-2","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1472_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12272-021-01366-y","volume":"45","author":"NT Kim","year":"2022","unstructured":"Kim NT, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2022) Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Arch Pharm Res 45(2):114\u2013121. https:\/\/doi.org\/10.1007\/s12272-021-01366-y","journal-title":"Arch Pharm Res"},{"key":"1472_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.phrs.2017.11.003","volume":"29","author":"SE Kjeldsen","year":"2018","unstructured":"Kjeldsen SE (2018) Hypertension and cardiovascular risk: general aspects. Pharmacol Res 29:95\u201399. https:\/\/doi.org\/10.1016\/j.phrs.2017.11.003","journal-title":"Pharmacol Res"},{"issue":"4","key":"1472_CR51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2967\/jnmt.110.077065","volume":"38","author":"WC Klingensmith","year":"2010","unstructured":"Klingensmith WC, Rhea KL, Wainwright EA, Hopper OW (2010) The gastric emptying study with oatmeal: reference range and reproducibility as a function of age and sex. J Nucl Med Technol 38(4):186\u2013190. https:\/\/doi.org\/10.2967\/jnmt.110.077065","journal-title":"J Nucl Med Technol"},{"issue":"10","key":"1472_CR52","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D (2016) Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacomet Syst Pharmacol 5(10):516\u2013531. https:\/\/doi.org\/10.1002\/psp4.12134","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"1472_CR53","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1592\/phco.23.6.720.32187","volume":"23","author":"CR Lee","year":"2003","unstructured":"Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1\/*1, *1\/*2, and *1\/*3 individuals. Pharmacotherapy 23(6):720\u2013725. https:\/\/doi.org\/10.1592\/phco.23.6.720.32187","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1472_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12272-016-0785-x","volume":"39","author":"HJ Lee","year":"2016","unstructured":"Lee HJ, Kim YH, Kim SH, Lee CM, Yang AY, Jang CG, Lee SY, Bae JW, Choi CI (2016) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast. Arch Pharm Res 39(7):1013\u20131019. https:\/\/doi.org\/10.1007\/s12272-016-0785-x","journal-title":"Arch Pharm Res"},{"issue":"11","key":"1472_CR55","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00228-018-2522-5","volume":"74","author":"HI Lee","year":"2018","unstructured":"Lee HI, Byeon JY, Kim YH, Lee CM, Choi CI, Jang CG, Bae JW, Lee YJ, Lee SY (2018) Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. Eur J Clin Pharmacol 74(11):1417\u20131426. https:\/\/doi.org\/10.1007\/s00228-018-2522-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1472_CR56","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s12272-019-01201-5","volume":"42","author":"CM Lee","year":"2019","unstructured":"Lee CM, Jung EH, Byeon JY, Kim SH, Jang CG, Lee YJ, Lee SY (2019) Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects. Arch Pharm Res 42(12):1101\u20131106. https:\/\/doi.org\/10.1007\/s12272-019-01201-5","journal-title":"Arch Pharm Res"},{"key":"1472_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-022-01394-2","author":"CM Lee","year":"2022","unstructured":"Lee CM, Kang P, Cho CK, Park HJ, Lee YJ, Bae JW, Choi CI, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Arch Pharm Res. https:\/\/doi.org\/10.1007\/s12272-022-01394-2","journal-title":"Arch Pharm Res"},{"issue":"9","key":"1472_CR58","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/biomedicines11092505","volume":"11","author":"R Magadmi","year":"2023","unstructured":"Magadmi R, Alyoubi R, Moshrif T, Bakhshwin D, Suliman BA, Kamel F, Jamal M, Burzangi AS, Basit S (2023) Polymorphisms in the drug transporter gene ABCB1 are associated with drug response in Saudi epileptic pediatric patients. Biomedicines 11(9):2505. https:\/\/doi.org\/10.3390\/biomedicines11092505","journal-title":"Biomedicines"},{"key":"1472_CR59","unstructured":"Mann JFE, Flack JM (2023) Choice of drug therapy in primary (essential) hypertension. https:\/\/www.uptodate.com\/contents\/choice-of-drug-therapy-in-primary-essential-hypertension#!. Accessed 06 Nov 2023"},{"issue":"8","key":"1472_CR60","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2165\/00003088-200140080-00004","volume":"40","author":"MR Marino","year":"2001","unstructured":"Marino MR, Vachharajani NN (2001) Drug interactions with irbesartan. Clin Pharmacokinet 40(8):605\u2013614. https:\/\/doi.org\/10.2165\/00003088-200140080-00004","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1472_CR61","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","volume":"38","author":"MR Marino","year":"1998","unstructured":"Marino MR, Langenbacher K, Ford NF, Uderman HD (1998a) Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 38(3):246\u2013255. https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04422.x","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1472_CR62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/j.1552-4604.1998.tb04434.x","volume":"38","author":"MR Marino","year":"1998","unstructured":"Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC (1998b) Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 38(4):347\u2013356. https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04434.x","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1472_CR63","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.xphs.2017.04.035","volume":"106","author":"N Marsousi","year":"2017","unstructured":"Marsousi N, Desmeules JA, Rudaz S, Daali Y (2017) Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J Pharm Sci 106(9):2380\u20132391. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.035","journal-title":"J Pharm Sci"},{"issue":"4","key":"1472_CR64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/cts.12623","volume":"12","author":"SJ McFeely","year":"2019","unstructured":"McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I (2019) Identification and evaluation of clinical substrates of organic anion transporting polypeptides 1B1 and 1B3. Clin Transl Sci 12(4):379\u2013387. https:\/\/doi.org\/10.1111\/cts.12623","journal-title":"Clin Transl Sci"},{"issue":"12","key":"1472_CR65","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12272-017-0976-0","volume":"40","author":"JS Min","year":"2017","unstructured":"Min JS, Bae SK (2017) Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. Arch Pharm Res 40(12):1356\u20131379. https:\/\/doi.org\/10.1007\/s12272-017-0976-0","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1472_CR66","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2133\/dmpk.dmpk-11-rv-099","volume":"27","author":"T Nakanishi","year":"2012","unstructured":"Nakanishi T, Tamai I (2012) Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet 27(1):106\u2013121. https:\/\/doi.org\/10.2133\/dmpk.dmpk-11-rv-099","journal-title":"Drug Metab Pharmacokinet"},{"issue":"10304","key":"1472_CR67","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2021) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet 398(10304):957\u2013980. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1","journal-title":"The Lancet"},{"issue":"6","key":"1472_CR68","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2133\/dmpk.20.452","volume":"20","author":"M Nishimura","year":"2005","unstructured":"Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20(6):452\u2013477. https:\/\/doi.org\/10.2133\/dmpk.20.452","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"1472_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2133\/dmpk.21.357","volume":"21","author":"M Nishimura","year":"2006","unstructured":"Nishimura M, Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21(5):357\u2013374. https:\/\/doi.org\/10.2133\/dmpk.21.357","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"1472_CR70","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1248\/yakushi.123.369","volume":"123","author":"M Nishimura","year":"2003","unstructured":"Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T (2003) Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessedby high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123(5):369\u2013375. https:\/\/doi.org\/10.1248\/yakushi.123.369","journal-title":"Yakugaku Zasshi"},{"key":"1472_CR71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/PGPM.S230201","volume":"12","author":"GH Oliveira-Paula","year":"2019","unstructured":"Oliveira-Paula GH, Pereira SC, Tanus-Santos JE, Lacchini R (2019) Pharmacogenomics and hypertension: current insights. Pharmgenomics Pers Med 12:341\u2013359. https:\/\/doi.org\/10.2147\/PGPM.S230201","journal-title":"Pharmgenomics Pers Med"},{"issue":"4","key":"1472_CR72","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clpt.2005.06.014","volume":"78","author":"JA Perini","year":"2005","unstructured":"Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G (2005) Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 78(4):362\u2013369. https:\/\/doi.org\/10.1016\/j.clpt.2005.06.014","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1472_CR73","first-page":"91","volume":"271","author":"L Perrier","year":"1994","unstructured":"Perrier L, Bourri\u00e9 M, Marti E, Tronquet C, Mass\u00e9 D, Berger Y, Magdalou J, Fabre G (1994) In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 271(1):91\u201399","journal-title":"J Pharmacol Exp Ther"},{"key":"1472_CR74","doi-asserted-by":"crossref","unstructured":"Poulin P, Schoenlein K, Theil FP (2001) Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90(4):436\u2013447. https:\/\/doi.org\/10.1002\/1520-6017(200104)90:4<436::aid-jps1002>3.0.co;2-p","DOI":"10.1002\/1520-6017(200104)90:4<436::AID-JPS1002>3.0.CO;2-P"},{"issue":"1","key":"1472_CR75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E","volume":"89","author":"P Poulin","year":"2000","unstructured":"Poulin P, Theil FP (2000) A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89(1):16\u201335. https:\/\/doi.org\/10.1002\/(SICI)1520-6017(200001)89:1%3c16::AID-JPS3%3e3.0.CO;2-E","journal-title":"J Pharm Sci"},{"issue":"1","key":"1472_CR76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jps.10005","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP (2002a) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91(1):129\u2013156. https:\/\/doi.org\/10.1002\/jps.10005","journal-title":"J Pharm Sci"},{"issue":"5","key":"1472_CR77","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/jps.10128","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP (2002b) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91(5):1358\u20131370. https:\/\/doi.org\/10.1002\/jps.10128","journal-title":"J Pharm Sci"},{"issue":"5","key":"1472_CR78","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/s0006-2952(98)00268-8","volume":"57","author":"AD Rodrigues","year":"1999","unstructured":"Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57(5):465\u2013480. https:\/\/doi.org\/10.1016\/s0006-2952(98)00268-8","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"1472_CR79","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/pharmaceutics12121200","volume":"12","author":"S R\u00fcdesheim","year":"2020","unstructured":"R\u00fcdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T (2020) Physiologically based pharmacokinetic modeling of metoprolol enantiomers and \u03b1-hydroxymetoprolol to describe CYP2D6 drug-gene interactions. Pharmaceutics 12(12):1200. https:\/\/doi.org\/10.3390\/pharmaceutics12121200","journal-title":"Pharmaceutics"},{"issue":"4","key":"1472_CR80","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/psp4.12776","volume":"11","author":"S R\u00fcdesheim","year":"2022","unstructured":"R\u00fcdesheim S, Selzer D, Fuhr U, Schwab M, Lehr T (2022) Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. CPT Pharmacomet Syst Pharmacol 11(4):494\u2013511. https:\/\/doi.org\/10.1002\/psp4.12776","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"11","key":"1472_CR81","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N (2015) Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos 43(11):1823\u20131837. https:\/\/doi.org\/10.1124\/dmd.115.065920","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"1472_CR82","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s12272-020-01294-3","volume":"43","author":"HB Shin","year":"2020","unstructured":"Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW (2020) ABCB1 c.2677G>T\/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Arch Pharm Res 43(11):1187\u20131196. https:\/\/doi.org\/10.1007\/s12272-020-01294-3","journal-title":"Arch Pharm Res"},{"issue":"9","key":"1472_CR83","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/jpm11090862","volume":"11","author":"G Song","year":"2021","unstructured":"Song G, Chung JE, Yee J, Lee KE, Park K, Gwak HS (2021) Effects of SLCO1B1 and SLCO1B3 genetic polymorphisms on valsartan pharmacokinetics in healthy Korean volunteers. J Pers Med 11(9):862. https:\/\/doi.org\/10.3390\/jpm11090862","journal-title":"J Pers Med"},{"issue":"1","key":"1472_CR84","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.09.002","volume":"141","author":"JC Stingl","year":"2014","unstructured":"Stingl JC, Bartels H, Viviani R, Lehmann M, Brockm\u00f6ller J (2014) Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 141(1):92\u2013116. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.002","journal-title":"Pharmacol Ther"},{"issue":"10","key":"1472_CR85","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10038-008-0324-9","volume":"53","author":"S Suwannakul","year":"2008","unstructured":"Suwannakul S, Ieiri I, Kimura M, Kawabata K, Kusuhara H, Hirota T, Irie S, Sugiyama Y, Higuchi S (2008) Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet 53(10):899\u2013904. https:\/\/doi.org\/10.1007\/s10038-008-0324-9","journal-title":"J Hum Genet"},{"issue":"3","key":"1472_CR86","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00008571-200104000-00006","volume":"11","author":"C Tang","year":"2001","unstructured":"Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Hecken AV, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD (2001) In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11(3):223\u2013235. https:\/\/doi.org\/10.1097\/00008571-200104000-00006","journal-title":"Pharmacogenetics"},{"issue":"3","key":"1472_CR87","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10928-022-09804-0","volume":"49","author":"A Tanveer","year":"2022","unstructured":"Tanveer A, Hussain K, Tasneem H, Arif I, Rashid M, Abbas N, Shamim R, Shah PA, Bukhari NI (2022) Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling. J Pharmacokinet Pharmacodyn 49(3):311\u2013323. https:\/\/doi.org\/10.1007\/s10928-022-09804-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"1472_CR88","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3109\/03639045.2014.950274","volume":"41","author":"L Wang","year":"2015","unstructured":"Wang L, Bao SH, Pan PP, Xia MM, Chen MC, Liang BQ, Dai DP, Cai JP, Hu GX (2015) Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm 41(8):1363\u20131367. https:\/\/doi.org\/10.3109\/03639045.2014.950274","journal-title":"Drug Dev Ind Pharm"},{"issue":"6","key":"1472_CR89","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra020021","volume":"348","author":"R Weinshilboum","year":"2003","unstructured":"Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348(6):529\u2013537. https:\/\/doi.org\/10.1056\/NEJMra020021","journal-title":"N Engl J Med"},{"issue":"6","key":"1472_CR90","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3748\/wjg.v9.i6.1342","volume":"9","author":"SY Wen","year":"2003","unstructured":"Wen SY, Wang H, Sun OJ, Wang SQ (2003) Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol: World J Gastroenterol 9(6):1342\u20131346. https:\/\/doi.org\/10.3748\/wjg.v9.i6.1342","journal-title":"World J Gastroenterol: World J Gastroenterol"},{"issue":"8","key":"1472_CR91","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s12272-022-01403-4","volume":"45","author":"SS Whang","year":"2022","unstructured":"Whang SS, Cho CK, Jung EH, Kang P, Park HJ, Lee YJ, Choi CI, Bae JW, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes. Arch Pharm Res 45(8):584\u2013595. https:\/\/doi.org\/10.1007\/s12272-022-01403-4","journal-title":"Arch Pharm Res"},{"key":"1472_CR92","unstructured":"World Health Organization (2021) The global health observatory: indicator metadata registry list: blood pressure\/hypertension. https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/3155. Accessed 06 Nov 2023"},{"key":"1472_CR93","doi-asserted-by":"publisher","first-page":"106258","DOI":"10.1016\/j.ejps.2022.106258","volume":"177","author":"H Yang","year":"2022","unstructured":"Yang H, Yang L, Zhong X, Jiang X, Zheng L, Wang L (2022) Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes. Eur J Pharm Sci 177:106258. https:\/\/doi.org\/10.1016\/j.ejps.2022.106258","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"1472_CR94","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","volume":"6","author":"X Zhuang","year":"2016","unstructured":"Zhuang X, Lu C (2016) PBPK modeling and simulation in drug research and development. Acta Pharm Sin B 6(5):430\u2013440. https:\/\/doi.org\/10.1016\/j.apsb.2016.04.004","journal-title":"Acta Pharm Sin B"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-023-01472-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T19:06:21Z","timestamp":1702753581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-023-01472-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":94,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s12272-023-01472-z","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}